Answers are grounded in this paper and cite their sources.
Evaluates RBC lifespan determinants in sickle cell disease, suggesting new transfusion therapy insights.
As donor RBC survival varies significantly between patients with sickle cell disease (SCD), it is important to identify determinants of RBC survival to allow for improvement of transfusion therapy. This study explored the determinants of donor and endogenous RBC survival in patients with SCD. RBC survival was quantified based on the fraction of RBCs containing hemoglobin A or S (flow cytometry) and 15 N-labeling curves, which were measured at baseline and in 6 blood samples post-transfusion. A mathematical model was developed to estimate RBC lifespans from these measurements. Associations between potential determinants and RBC lifespan were analyzed using linear regression. Twenty-four patients (median age 22 years (IQR: 18 - 39)), treated with a chronic transfusion regimen, either top-up ( n =12) or exchange transfusion ( n =12), were included. In the top-up group, median donor and endogenous RBC lifespan were 108 days (IQR: 64 - 118) and 20 days (IQR: 16 - 25). In the exchange group, median donor and endogenous RBC lifespan were 68 days (IQR: 63 - 100) and 34 days (IQR: 29 - 50). Donor RBC lifespan was associated with recipient plasma levels of vascular endothelial growth factor A. Endogenous RBC lifespan was positively associated with exchange transfusion (compared to top-up) and inversely associated with plasma levels of interleukin-1β. This study demonstrates that our novel approach for tracking RBC kinetics provides a robust and less invasive alternative to biotin labeling. Although this study provides interesting hints at determinants of RBC lifespan in SCD, larger studies are needed to confirm the determinants.
No takes yet. Share an insight, caveat, or question.
Ligt et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: